Biogen
Tracked across 6 events · 44 articles · First seen Feb 19, 2026 · Last active May 28, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Tech
Biogen announced compelling topline results from its Phase 2 CELIA study for diranersen (BIIB080), an investigational antisense oligonucleotide (ASO) therapy targeting tau in individuals with early Alzheimer's disease. The study demonstrated robust reductions in tau…
Impact: Biogen announced compelling topline results from its Phase 2 CELIA study for diranersen, showing robust biomarker impact and cognitive benefit in early Alzheimer's disease, despite not meeting the primary endpoint for dose response. This positive data gives Biogen confidence to advance diranersen to registrational development.
May 14, 2026 · 7 articles
Tech
Impact: Biogen produces lecanemab (Leqembi), an anti-amyloid drug whose efficacy was challenged by the Cochrane review, which could negatively affect its market performance.
Apr 16, 2026 · 6 articles
Regulatory
The United States — Food and Drug Administration has extended the review period for Eisai's supplemental Biologics License Application (sBLA) for Lecanemab Iqlik, a once-weekly subcutaneous injection of lecanemab irmb for early Alzheimer's disease. The…
Impact: Biogen, a partner with Eisai, is affected by the FDA's decision to extend the review period for Lecanemab IQLIK, pushing back the potential approval and commercialization of the drug. This delay impacts Biogen's financial projections and market strategy for Alzheimer's treatments.
May 08, 2026 · 13 articles
Tech
Impact: Biogen is a funding partner for the project, supporting the research into Alzheimer s disease biomarkers.
Feb 19, 2026 · 6 articles
Business
Eisai, in collaboration with BioArctic, announced a projected revenue of JPY 143.5 billion (approximately SEK 8.4 billion) for their Alzheimer's drug, Lecanemab, for fiscal year 2026 (April 2026 - March 2027). This represents a 63%…
Impact: Biogen entered into a joint development and commercialization agreement for lecanemab with Eisai in 2014 and is involved in the AHEAD 3-45 clinical study.
May 15, 2026 · 6 articles
Business
AstronauTx, a biotechnology company focused on treating Alzheimer's Disease and other neurological disorders, announced the appointments of Dr. Michelle Mellion as Chief Medical Officer (CMO) and Deb Gouveia as Vice President, Clinical Operations and Development…
Impact: Dr. Michelle Mellion previously held positions at Biogen, contributing to programs spanning remyelination.
May 12, 2026 · 6 articles
100
Biogen announced resultsBiogen Diranersen Phase 2...
90
Biogen plans to advanceBiogen Diranersen Phase 2...
80
Eisai announced review extension BiogenLeqembi Iqlik PDUFA Date Extended
50
United States — Food and Drug Administration granted Fast Track BiogenBiogen Diranersen Phase 2...
30
Biogen exercised license option Ionis PharmaceuticalsBiogen Diranersen Phase 2...
NEWSDESK
Track Biogen live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard